<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35390501</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2212-8778</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular metabolism</Title>
          <ISOAbbreviation>Mol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Urocortin 2 promotes hypertrophy and enhances skeletal muscle function through cAMP and insulin/IGF-1 signaling pathways.</ArticleTitle>
        <Pagination>
          <StartPage>101492</StartPage>
          <MedlinePgn>101492</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">101492</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molmet.2022.101492</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2212-8778(22)00061-8</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Although it is well established that urocortin 2 (Ucn2), a peptide member of the corticotrophin releasing factor (CRF) family, and its specific corticotrophin-releasing factor 2 receptor (CRF2R) are highly expressed in skeletal muscle, the role of this peptide in the regulation of skeletal muscle mass and protein metabolism remains elusive.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">To elucidate the mechanisms how Ucn2 directly controls protein metabolism in skeletal muscles of normal mice, we carried out genetic tools, physiological and molecular analyses of muscles in vivo and in vitro.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Here, we demonstrated that Ucn2 overexpression activated cAMP signaling and promoted an expressive muscle hypertrophy associated with higher rates of protein synthesis and activation of Akt/mTOR and ERK1/2 signaling pathways. Furthermore, Ucn2 induced a decrease in mRNA levels of atrogin-1 and in autophagic flux inferred by an increase in the protein content of LC3-I, LC3-II and p62. Accordingly, Ucn2 reduced both the transcriptional activity of FoxO in vivo and the overall protein degradation in vitro through an inhibition of lysosomal proteolytic activity. In addition, we demonstrated that Ucn2 induced a fast-to-slow fiber type shift and improved fatigue muscle resistance, an effect that was completely blocked in muscles co-transfected with mitogen-activated protein kinase phosphatase 1 (MKP-1), but not with dominant-negative Akt mutant (Aktmt).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data suggest that Ucn2 triggers an anabolic and anti-catabolic response in skeletal muscle of normal mice probably through the activation of cAMP cascade and participation of Akt and ERK1/2 signaling. These findings open new perspectives in the development of therapeutic strategies to cope with the loss of muscle mass.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lautherbach</LastName>
            <ForeName>Natalia</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Biochemistry/Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: nutriennes@yahoo.com.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonçalves</LastName>
            <ForeName>Dawit A P</ForeName>
            <Initials>DAP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Exercise Physiology Laboratory, School of Physical Education, Physiotherapy and Occupational Therapy, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address: dawit@ufmg.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silveira</LastName>
            <ForeName>Wilian A</ForeName>
            <Initials>WA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Biochemistry, Pharmacology and Physiology, Institute of Biological and Natural Sciences, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil. Electronic address: wilian.silveira@uftm.edu.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paula-Gomes</LastName>
            <ForeName>Sílvia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry/Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil. Electronic address: silvia.gomes@ufop.edu.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Valentim</LastName>
            <ForeName>Rafael Rossi</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: rafaelrossiphd@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zanon</LastName>
            <ForeName>Neusa M</ForeName>
            <Initials>NM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: neuzanon@yahoo.com.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pereira</LastName>
            <ForeName>Marcelo G</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: pereiramg@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyabara</LastName>
            <ForeName>Elen H</ForeName>
            <Initials>EH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: elenm@usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Navegantes</LastName>
            <ForeName>Luiz C C</ForeName>
            <Initials>LCC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: navegantes@fmrp.usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kettelhut</LastName>
            <ForeName>Isis C</ForeName>
            <Initials>IC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Biochemistry/Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: idckette@fmrp.usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Metab</MedlineTA>
        <NlmUniqueID>101605730</NlmUniqueID>
        <ISSNLinking>2212-8778</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054832">Urocortins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C518358">urocortin 2, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>67763-96-6</RegistryNumber>
          <NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-60-2</RegistryNumber>
          <NameOfSubstance UI="D000324">Adrenocorticotropic Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9015-71-8</RegistryNumber>
          <NameOfSubstance UI="D003346">Corticotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000324" MajorTopicYN="N">Adrenocorticotropic Hormone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003346" MajorTopicYN="N">Corticotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006984" MajorTopicYN="N">Hypertrophy</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="Y">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054832" MajorTopicYN="N">Urocortins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Fatigue resistance</Keyword>
        <Keyword MajorTopicYN="N">Hypertrophy</Keyword>
        <Keyword MajorTopicYN="N">Urocortin 2</Keyword>
        <Keyword MajorTopicYN="N">cAMP</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>20</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35390501</ArticleId>
        <ArticleId IdType="pmc">PMC9035725</ArticleId>
        <ArticleId IdType="doi">10.1016/j.molmet.2022.101492</ArticleId>
        <ArticleId IdType="pii">S2212-8778(22)00061-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., et al.  Urocortin II : a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(5):2–7.</Citation>
        </Reference>
        <Reference>
          <Citation>Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Medicine. 2001;7(5):605–611.</Citation>
        </Reference>
        <Reference>
          <Citation>Kishimoto T., Ilt R.V.P., Lin C.R., Rosenfeldt M.G. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:1108–1112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC42647</ArticleId>
            <ArticleId IdType="pubmed">7755719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovenberg T.W., Liaw C.W., Grigoriadist D.E., Clevenger W., Chalmerst D.T., Souzat E.B.D.E., et al.  Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:836–840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC42715</ArticleId>
            <ArticleId IdType="pubmed">7846062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perrin M.H., Vale W.W. Corticotropin releasing factor receptors and their ligand family. Annals of the New York Academy of Sciences. 1999;885:312–328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10816663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen A., Blount A.M.Y., Vaughan J., Brar B., Foundation C., Biology P., et al.  Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids. Endocrinology. 2004;145(5):2445–2457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14736736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coste S.C., Kesterson R.A., Heldwein K.A., Stevens S.L., Heard A.D., Hollis J.H., et al.  Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nature Genetics. 2000;24(4):403–409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10742107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., et al.  Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genetics. 2000;24(4):410–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10742108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen A., Vaughan J., Vale W.W. Glucocorticoids regulate the expression of the mouse urocortin II gene : a putative connection between the corticotropin-releasing factor receptor pathways. Molecular Endocrinology. 2003;17(8):1622–1639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12764078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neufeld-Cohen A., Tsoory M.M., Evans A.K., Getselter D., Gil S., Lowry C.A., et al.  A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(44):19020–19025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2973872</ArticleId>
            <ArticleId IdType="pubmed">20937857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bale T.L., Hoshijima M., Gu Y., Dalton N., Anderson K.R., Lee K.-F., et al.  The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(10):3697–3702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC373525</ArticleId>
            <ArticleId IdType="pubmed">14990799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiley K.E., Davenport A.P. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. British Journal of Pharmacology. 2004;143(4):508–514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1575420</ArticleId>
            <ArticleId IdType="pubmed">15381637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen A., Brar B., Choi C.S., Rousso D., Vaughan J., Kuperman Y., et al.  Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(44):16580–16585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1637624</ArticleId>
            <ArticleId IdType="pubmed">17050686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinkle R.T., Donnelly E., Cody D.B., Bauer M.B., Isfort R.J. Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. Endocrinology. 2003;144(11):4939–4946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12960070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinkle R.T., Donnelly E., Cody D.B., Samuelsson S., Lange J.S., Bauer M.B., et al.  Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions. American Journal of Physiology. Endocrinology and Metabolism. 2003;285(4):E889–E898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12959937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borg M.L., Massart J., De Castro Barbosa T., Archilla-Ortega A., Smith J.A.B., Lanner J.T., et al.  Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity-induced insulin resistance. J Cachexia Sarcopenia Muscle. 2021;12(5):1232–1248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8517345</ArticleId>
            <ArticleId IdType="pubmed">34342159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuperman Y., Issler O., Vaughan J., Bilezikjian L., Vale W., Chen A. Expression and regulation of corticotropin-releasing factor receptor type 2β in developing and mature mouse skeletal muscle. Molecular Endocrinology. 2011;25(1):157–169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3388898</ArticleId>
            <ArticleId IdType="pubmed">21084379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lira E.C., Gonçalves D.A.P., Parreiras-E-Silva L.T., Zanon N.M., Kettelhut I.C., Navegantes L.C.C. Phosphodiesterase-4 inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles. Muscle &amp; Nerve. 2011;44(3):371–381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21996797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonçalves D.A., Silveira W.A., Manfredi L.H., Graça F.A., Armani A., Bertaggia E., et al.  Insulin/IGF1 signalling mediates the effects of β2 -adrenergic agonist on muscle proteostasis and growth. J Cachexia Sarcopenia Muscle. 2019;10(2):455–475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6463755</ArticleId>
            <ArticleId IdType="pubmed">30932373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., et al.  Mechanism of activation of protein kinase B by insulin and IGF-1. The EMBO Journal. 1996;15(23):6541–6551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC452479</ArticleId>
            <ArticleId IdType="pubmed">8978681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butler A.A., Yakar S., Gewolb I.H., Karas M., Okubo Y., LeRoith D. Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology. 1998;121(1):19–26.</Citation>
        </Reference>
        <Reference>
          <Citation>LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews. 1995;16(2):143–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7540132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myers M.G., Grammer T.C., Wang L.M., Sun X.J., Pierce J.H., Blenis J., et al.  Insulin receptor substrate-1 mediates phosphatidylinositol 3’-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. Journal of Biological Chemistry. 1994;269(46):28783–28789.</Citation>
        </Reference>
        <Reference>
          <Citation>Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., et al.  Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature Cell Biology. 2001;3(11):1014–1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11715023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K., Zhu T., Guan K., Arbor A. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14651849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazaki M., Takemasa T. TSC2/Rheb signaling mediates ERK-dependent regulation of mTORC1 activity in C2C12 myoblasts. FEBS Open Bio. 2017;7(3):424–433.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang J.-Y., Zong C.S., Xia W., Yamaguchi H., Ding Q., Xie X., et al.  ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nature Cell Biology. 2008;10(2):138–148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2376808</ArticleId>
            <ArticleId IdType="pubmed">18204439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S.K., Srivastava R.K., Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. Journal of Molecular Signaling. 2010;5(10)</Citation>
        </Reference>
        <Reference>
          <Citation>Mammucari C., Milan G., Romanello V., Masiero E., Rudolf R., Del Piccolo P., et al.  FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metabolism. 2007;6(6):458–471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18054315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117(3):399–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3619734</ArticleId>
            <ArticleId IdType="pubmed">15109499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonaldo P., Sandri M. Cellular and molecular mechanisms of muscle atrophy. Disease Models &amp; Mechanisms. 2013;6(1):25–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3529336</ArticleId>
            <ArticleId IdType="pubmed">23268536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milan G., Romanello V., Pescatore F., Armani A., Paik J.-H., Frasson L., et al.  Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nature Communications. 2015;6(6670)</Citation>
        </Reference>
        <Reference>
          <Citation>Fernandez-Marcos P.J., Auwerx J. Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. American Journal of Clinical Nutrition. 2011;93(4) 884S–890S.</Citation>
        </Reference>
        <Reference>
          <Citation>Singh S., Simpson R.L., Bennett R.G. Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α) Journal of Biological Chemistry. 2015;290(2):950–959.</Citation>
        </Reference>
        <Reference>
          <Citation>Handschin C., Kobayashi Y.M., Chin S., Seale P., Campbell K.P., Spiegelman B.M. PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes &amp; Development. 2007;21(7):770–783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1838529</ArticleId>
            <ArticleId IdType="pubmed">17403779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X.-Y., Tse M.C.L., Hu X., Jia W.-H., Du G.-H., Chan C.B. Interaction of CREB and PGC-1α induces fibronectin type III domain-containing protein 5 expression in C2C12 myotubes. Cellular Physiology and Biochemistry. 2018;50(4):1574–1584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30359971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murgia M., Serrano A.L., Calabria E., Pallafacchina G., Lomo T., Schiaffino S. Ras is involved in nerve-activity-dependent regulation of muscle genes. Nature Cell Biology. 2000;2(3):142–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10707084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Pessin J.E. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Current Opinion in Clinical Nutrition and Metabolic Care. 2013;16(3):243–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4327989</ArticleId>
            <ArticleId IdType="pubmed">23493017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao X.-F., Zhou Y., Wang D.-Y., Lew K.-S., Richards A.M., Wang P. Urocortin-2 suppression of p38-MAPK signaling as an additional mechanism for ischemic cardioprotection. Molecular and Cellular Biochemistry. 2015;398(1–2):135–146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25245818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navegantes L.C., Resano N.M., Migliorini R.H., Kettelhut I.C. Effect of guanethidine-induced adrenergic blockade on the different proteolytic systems in rat skeletal muscle. American Journal of Physiology. 1999;277(5):E883–E889.</Citation>
        </Reference>
        <Reference>
          <Citation>Ryall J.G., Plant D.R., Gregorevic P., Sillence M.N., Lynch G.S. Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. The Journal of Physiology. 2004;555(Pt 1):175–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1664816</ArticleId>
            <ArticleId IdType="pubmed">14617677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan S., Head S.I. Age- and gender-related changes in contractile properties of non-atrophied EDL muscle. PLoS One. 2010;5(8)</Citation>
        </Reference>
        <Reference>
          <Citation>Waalkes T.P., Udenfriend S. A fluorometric method for the estimation of tyrosine in plasma and tissues. The Journal of Laboratory and Clinical Medicine. 1957;50(5):733–736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13476030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman C.A., Mabrey D.M., Frey J.W., Miu M.H., Schmidt E.K., Pierre P., et al.  Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. Federation of American Societies for Experimental Biology Journal. 2011;25(3):1028–1039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3042844</ArticleId>
            <ArticleId IdType="pubmed">21148113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju J., Varadhachary A.S., Miller S.E., Weihl C.C. Quantitation of “autophagic flux” in mature skeletal muscle. Autophagy. 2010;6(7):929–935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3039739</ArticleId>
            <ArticleId IdType="pubmed">20657169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaughan J.M., Donaldson C.J., Fischer W.H., Perrin M.H., Rivier J.E., Sawchenko P.E., et al.  Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products. Endocrinology. 2013;154(4):1553–1564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3602626</ArticleId>
            <ArticleId IdType="pubmed">23493376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399(6736):601–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10376603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J.J., Zhang L., Bennett A.M. The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation. Molecular and Cellular Biology. 2005;25(11):4792–4803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1140620</ArticleId>
            <ArticleId IdType="pubmed">15899879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankiv S., Clausen T.H., Lamark T., Brech A., Bruun J.A., Outzen H., et al.  p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. Journal of Biological Chemistry. 2007;282(33):24131–24145.</Citation>
        </Reference>
        <Reference>
          <Citation>de Rooij J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., et al.  Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396(6710):474–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9853756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Reviews Molecular Cell Biology. 2011;12(1):21–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3390257</ArticleId>
            <ArticleId IdType="pubmed">21157483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyronnet S. Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochemical Pharmacology. 2000;60(8):1237–1243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11007962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng J., Klionsky D.J. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. “Protein modifications: beyond the usual suspects” review series. EMBO Reports. 2008;9(9):859–864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2529362</ArticleId>
            <ArticleId IdType="pubmed">18704115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjørkøy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., et al.  p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. The Journal of Cell Biology. 2005;171(4):603–614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2171557</ArticleId>
            <ArticleId IdType="pubmed">16286508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., et al.  FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metabolism. 2007;6(6):472–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18054316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Proud C.G. Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circulation Research. 2002;91(9):821–829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12411397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelleher R.J., Govindarajan A., Jung H.-Y., Kang H., Tonegawa S. Translational control by MAPK signaling in long-term synaptic plasticity and memory. Cell. 2004;116(3):467–479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15016380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin J., Wu H., Tarr P.T., Zhang C.-Y., Wu Z., Boss O., et al.  Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002;418(6899):797–801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12181572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinkle R.T., Donnelly E., Cody D.B., Bauer M.B., Sheldon R.J., Isfort R.J. Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force. Journal of Muscle Research &amp; Cell Motility. 2004;25(7):539–547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15711884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reutenauer-patte J., Boittin F., Patthey-vuadens O., Ruegg U.T., Dorchies O.M. Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and epac-dependent pathways. AJPA. 2012;180(2):749–762.</Citation>
        </Reference>
        <Reference>
          <Citation>Hall J.E., Kaczor J.A.N.J., Hettinga B.P. Effects of a CRF2R agonist and exercise on mdx and wildtype skeletal muscle. Muscle &amp; Nerve. 2007;36(3):336–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17503504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jesinkey S.R., Korrapati M.C., Rasbach K.A., Beeson C.C., Schnellmann R.G. Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice. Journal of Pharmacology and Experimental Therapeutics. 2014;351(3):663–673.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang W., Yano N., Deng M., Mao Q., Shaw S.K., Tseng Y.-T. β-Adrenergic receptor-PI3K signaling crosstalk in mouse heart: elucidation of immediate downstream signaling cascades. PLoS One. 2011;6(10)</Citation>
        </Reference>
        <Reference>
          <Citation>Liu D., Bordicchia M., Zhang C., Fang H., Wei W., Li J.-L., et al.  Activation of mTORC1 is essential for β-adrenergic stimulation of adipose browning. Journal of Clinical Investigation. 2016;126(5):1704–1716.</Citation>
        </Reference>
        <Reference>
          <Citation>Przygodda F., Lautherbach N., Buzelle S.L., Goncalves D.A., Assis A.P., Paula-Gomes S., et al.  Sympathetic innervation suppresses the autophagic-lysosomal system in brown adipose tissue under basal and cold-stimulated conditions. Journal of Applied Physiology. 2020;128(4):855–871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32027543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baviera A.M., Zanon N.M., Navegantes L.C.C., Kettelhut I.C. Involvement of cAMP/Epac/PI3K-dependent pathway in the antiproteolytic effect of epinephrine on rat skeletal muscle. Molecular and Cellular Endocrinology. 2010;315(1–2):104–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19804812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navegantes L.C.C., Resano N.M.Z., Migliorini R.H., Kettelhut I.C. Catecholamines inhibit Ca(2+)-dependent proteolysis in rat skeletal muscle through beta(2)-adrenoceptors and cAMP. American Journal of Physiology. Endocrinology and Metabolism. 2001;281(3):E449–E454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11500299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navegantes L.C.C., Resano N.M.Z., Migliorini R.H. Role of adrenoceptors and cAMP on the catecholamine- induced inhibition of proteolysis in rat skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism. 2000;279(3):E663–E668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10950836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryall J.G., Sillence M.N., Lynch G.S. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. British Journal of Pharmacology. 2006;147(6):587–595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1751341</ArticleId>
            <ArticleId IdType="pubmed">16432501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonçalves D. a P., Silveira W.a., Lira E.C., Graça F.a., Paula-Gomes S., Zanon N.M., et al.  Clenbuterol suppresses proteasomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of Akt. American Journal of Physiology. Endocrinology and Metabolism. 2012;302(1):E123–E133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21952035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costelli P., García-Martínez C., Llovera M., Carbó N., López-Soriano F.J., Agell N., et al.  Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. Journal of Clinical Investigation. 1995;95(5):2367–2372.</Citation>
        </Reference>
        <Reference>
          <Citation>Lira E.C., Graca F.A., Goncalves D.A.P., Zanon N.M., Baviera A.M., Strindberg L., et al.  Cyclic adenosine monophosphate-phosphodiesterase inhibitors reduce skeletal muscle protein catabolism in septic rats. Shock. 2007;27(6):687–694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17505310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baviera A.M., Zanon N.M., Carvalho Navegantes L.C., Migliorini R.H., do Carmo Kettelhut I. Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats. American Journal of Physiology. Endocrinology and Metabolism. 2007;292(3):E702–E708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17077345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Handschin C., Rhee J., Lin J., Tarr P.T., Spiegelman B.M. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(12):7111–7116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC165838</ArticleId>
            <ArticleId IdType="pubmed">12764228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herzig S., Long F., Jhala U.S., Hedrick S., Quinn R., Bauer A., et al.  CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;413(6852):179–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11557984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandri M., Lin J., Handschin C., Yang W., Arany Z.P., Lecker S.H., et al.  PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(44):16260–16265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1637570</ArticleId>
            <ArticleId IdType="pubmed">17053067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng T., Li P., Yin X., Yan Z. PGC-1α promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac cachexia in mice. American Journal Of Pathology. 2011;178(4):1738–1748.</Citation>
        </Reference>
        <Reference>
          <Citation>Silveira W.A., Gonçalves D.A., Machado J., Lautherbach N., Lustrino D., Marcelo S.P., et al.  cAMP-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice. The FASEB Journal. 2020;34(9):12946–12962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32772437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borg M.L., Massart J., Schönke M., Barbosa T.D.C., Guo L., Wade M., et al.  Modified UCN2 peptide acts as an insulin sensitizer in skeletal muscle of obese mice. Diabetes. 2019;68(7):1403–1414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31010957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chao H., Li H., Grande R., Lira V., Yan Z., Harris T.E., et al.  Involvement of mTOR in type 2 CRF receptor inhibition of insulin signaling in muscle cells. Molecular Endocrinology. 2015;29(6):831–841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4447643</ArticleId>
            <ArticleId IdType="pubmed">25875045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mei F.C., Qiao J., Tsygankova O.M., Meinkoth J.L., Quilliam L.A., Cheng X. Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. Journal of Biological Chemistry. 2002;277(13):11497–11504.</Citation>
        </Reference>
        <Reference>
          <Citation>Brennesvik E.O., Ktori C., Ruzzin J., Jebens E., Shepherd P.R., Jensen J. Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline. Cellular Signalling. 2005;17(12):1551–1559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15908181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keiper M., Stope M.B., Szatkowski D., Böhm A., Tysack K., Vom Dorp F., et al.  Epac- and Ca2+ -controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. Journal of Biological Chemistry. 2004;279(45):46497–46508.</Citation>
        </Reference>
        <Reference>
          <Citation>Jones N.C., Fedorov Y.V., Rosenthal R.S. ERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusion. Journal of Cellular Physiology. 2001;186(1):104–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11147804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokoyama T., Takano K., Yoshida A., Katada F., Sun P., Takenawa T., et al.  DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation. The Journal of Cell Biology. 2007;177(5):781–793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2064279</ArticleId>
            <ArticleId IdType="pubmed">17535970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.a., Kimball T.R., Klevitsky R., et al.  The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. The EMBO Journal. 2000;19(23):6341–6350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC305855</ArticleId>
            <ArticleId IdType="pubmed">11101507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueyama T., Kawashima S., Sakoda T., Rikitake Y., Ishida T., Kawai M., et al.  Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. Journal of Molecular and Cellular Cardiology. 2000;32(6):947–960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10888249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H., Scheffler J.M., Zeng C., Pleitner J.M., Hannon K.M., Grant A.L., et al.  Mitogen-activated protein kinase signaling is necessary for the maintenance of skeletal muscle mass. American Journal of Physiology - Cell Physiology. 2009;296(5):C1040–C1048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19295173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H., Zeng C., Ricome A., Hannon K.M., Grant A.L., Gerrard D.E. Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles. American Journal of Physiology - Cell Physiology. 2007;292(5):C1681–C1689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17151143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinkle R.T., Lefever F.R., Dolan E.T., Reichart D.L., Dietrich J.A., Gropp K.E., et al.  Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice. BMC Medicine. 2007;5(18)</Citation>
        </Reference>
        <Reference>
          <Citation>Chanalaris A., Lawrence K.M., Stephanou A., Knight R.D., Hsu S.Y., Hsueh A.J.W., et al.  Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. Journal of Molecular and Cellular Cardiology. 2003;35(10):1295–1305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14519439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(37):13489–13494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC518784</ArticleId>
            <ArticleId IdType="pubmed">15342917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brar B.K., Jonassen A.K., Egorina E.M., Chen A., Negro A., Perrin M.H., et al.  Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 2004;145(1):24–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12970163</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35390501</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2212-8778</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular metabolism</Title>
          <ISOAbbreviation>Mol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Urocortin 2 promotes hypertrophy and enhances skeletal muscle function through cAMP and insulin/IGF-1 signaling pathways.</ArticleTitle>
        <Pagination>
          <StartPage>101492</StartPage>
          <MedlinePgn>101492</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">101492</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molmet.2022.101492</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S2212-8778(22)00061-8</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Although it is well established that urocortin 2 (Ucn2), a peptide member of the corticotrophin releasing factor (CRF) family, and its specific corticotrophin-releasing factor 2 receptor (CRF2R) are highly expressed in skeletal muscle, the role of this peptide in the regulation of skeletal muscle mass and protein metabolism remains elusive.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">To elucidate the mechanisms how Ucn2 directly controls protein metabolism in skeletal muscles of normal mice, we carried out genetic tools, physiological and molecular analyses of muscles in vivo and in vitro.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Here, we demonstrated that Ucn2 overexpression activated cAMP signaling and promoted an expressive muscle hypertrophy associated with higher rates of protein synthesis and activation of Akt/mTOR and ERK1/2 signaling pathways. Furthermore, Ucn2 induced a decrease in mRNA levels of atrogin-1 and in autophagic flux inferred by an increase in the protein content of LC3-I, LC3-II and p62. Accordingly, Ucn2 reduced both the transcriptional activity of FoxO in vivo and the overall protein degradation in vitro through an inhibition of lysosomal proteolytic activity. In addition, we demonstrated that Ucn2 induced a fast-to-slow fiber type shift and improved fatigue muscle resistance, an effect that was completely blocked in muscles co-transfected with mitogen-activated protein kinase phosphatase 1 (MKP-1), but not with dominant-negative Akt mutant (Aktmt).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data suggest that Ucn2 triggers an anabolic and anti-catabolic response in skeletal muscle of normal mice probably through the activation of cAMP cascade and participation of Akt and ERK1/2 signaling. These findings open new perspectives in the development of therapeutic strategies to cope with the loss of muscle mass.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier GmbH.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lautherbach</LastName>
            <ForeName>Natalia</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Biochemistry/Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: nutriennes@yahoo.com.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gonçalves</LastName>
            <ForeName>Dawit A P</ForeName>
            <Initials>DAP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Exercise Physiology Laboratory, School of Physical Education, Physiotherapy and Occupational Therapy, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address: dawit@ufmg.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silveira</LastName>
            <ForeName>Wilian A</ForeName>
            <Initials>WA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Biochemistry, Pharmacology and Physiology, Institute of Biological and Natural Sciences, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil. Electronic address: wilian.silveira@uftm.edu.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paula-Gomes</LastName>
            <ForeName>Sílvia</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biochemistry/Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil. Electronic address: silvia.gomes@ufop.edu.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Valentim</LastName>
            <ForeName>Rafael Rossi</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: rafaelrossiphd@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zanon</LastName>
            <ForeName>Neusa M</ForeName>
            <Initials>NM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: neuzanon@yahoo.com.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pereira</LastName>
            <ForeName>Marcelo G</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: pereiramg@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyabara</LastName>
            <ForeName>Elen H</ForeName>
            <Initials>EH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: elenm@usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Navegantes</LastName>
            <ForeName>Luiz C C</ForeName>
            <Initials>LCC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: navegantes@fmrp.usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kettelhut</LastName>
            <ForeName>Isis C</ForeName>
            <Initials>IC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil; Department of Biochemistry/Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. Electronic address: idckette@fmrp.usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Metab</MedlineTA>
        <NlmUniqueID>101605730</NlmUniqueID>
        <ISSNLinking>2212-8778</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054832">Urocortins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C518358">urocortin 2, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>67763-96-6</RegistryNumber>
          <NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-60-2</RegistryNumber>
          <NameOfSubstance UI="D000324">Adrenocorticotropic Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9015-71-8</RegistryNumber>
          <NameOfSubstance UI="D003346">Corticotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000324" MajorTopicYN="N">Adrenocorticotropic Hormone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003346" MajorTopicYN="N">Corticotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006984" MajorTopicYN="N">Hypertrophy</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="Y">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054832" MajorTopicYN="N">Urocortins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Fatigue resistance</Keyword>
        <Keyword MajorTopicYN="N">Hypertrophy</Keyword>
        <Keyword MajorTopicYN="N">Urocortin 2</Keyword>
        <Keyword MajorTopicYN="N">cAMP</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>20</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35390501</ArticleId>
        <ArticleId IdType="pmc">PMC9035725</ArticleId>
        <ArticleId IdType="doi">10.1016/j.molmet.2022.101492</ArticleId>
        <ArticleId IdType="pii">S2212-8778(22)00061-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., et al.  Urocortin II : a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(5):2–7.</Citation>
        </Reference>
        <Reference>
          <Citation>Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Medicine. 2001;7(5):605–611.</Citation>
        </Reference>
        <Reference>
          <Citation>Kishimoto T., Ilt R.V.P., Lin C.R., Rosenfeldt M.G. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:1108–1112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC42647</ArticleId>
            <ArticleId IdType="pubmed">7755719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovenberg T.W., Liaw C.W., Grigoriadist D.E., Clevenger W., Chalmerst D.T., Souzat E.B.D.E., et al.  Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:836–840.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC42715</ArticleId>
            <ArticleId IdType="pubmed">7846062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perrin M.H., Vale W.W. Corticotropin releasing factor receptors and their ligand family. Annals of the New York Academy of Sciences. 1999;885:312–328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10816663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen A., Blount A.M.Y., Vaughan J., Brar B., Foundation C., Biology P., et al.  Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids. Endocrinology. 2004;145(5):2445–2457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14736736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coste S.C., Kesterson R.A., Heldwein K.A., Stevens S.L., Heard A.D., Hollis J.H., et al.  Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nature Genetics. 2000;24(4):403–409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10742107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., et al.  Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genetics. 2000;24(4):410–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10742108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen A., Vaughan J., Vale W.W. Glucocorticoids regulate the expression of the mouse urocortin II gene : a putative connection between the corticotropin-releasing factor receptor pathways. Molecular Endocrinology. 2003;17(8):1622–1639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12764078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neufeld-Cohen A., Tsoory M.M., Evans A.K., Getselter D., Gil S., Lowry C.A., et al.  A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(44):19020–19025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2973872</ArticleId>
            <ArticleId IdType="pubmed">20937857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bale T.L., Hoshijima M., Gu Y., Dalton N., Anderson K.R., Lee K.-F., et al.  The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(10):3697–3702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC373525</ArticleId>
            <ArticleId IdType="pubmed">14990799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiley K.E., Davenport A.P. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. British Journal of Pharmacology. 2004;143(4):508–514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1575420</ArticleId>
            <ArticleId IdType="pubmed">15381637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen A., Brar B., Choi C.S., Rousso D., Vaughan J., Kuperman Y., et al.  Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(44):16580–16585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1637624</ArticleId>
            <ArticleId IdType="pubmed">17050686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinkle R.T., Donnelly E., Cody D.B., Bauer M.B., Isfort R.J. Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. Endocrinology. 2003;144(11):4939–4946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12960070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinkle R.T., Donnelly E., Cody D.B., Samuelsson S., Lange J.S., Bauer M.B., et al.  Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions. American Journal of Physiology. Endocrinology and Metabolism. 2003;285(4):E889–E898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12959937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borg M.L., Massart J., De Castro Barbosa T., Archilla-Ortega A., Smith J.A.B., Lanner J.T., et al.  Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity-induced insulin resistance. J Cachexia Sarcopenia Muscle. 2021;12(5):1232–1248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8517345</ArticleId>
            <ArticleId IdType="pubmed">34342159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuperman Y., Issler O., Vaughan J., Bilezikjian L., Vale W., Chen A. Expression and regulation of corticotropin-releasing factor receptor type 2β in developing and mature mouse skeletal muscle. Molecular Endocrinology. 2011;25(1):157–169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3388898</ArticleId>
            <ArticleId IdType="pubmed">21084379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lira E.C., Gonçalves D.A.P., Parreiras-E-Silva L.T., Zanon N.M., Kettelhut I.C., Navegantes L.C.C. Phosphodiesterase-4 inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles. Muscle &amp; Nerve. 2011;44(3):371–381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21996797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonçalves D.A., Silveira W.A., Manfredi L.H., Graça F.A., Armani A., Bertaggia E., et al.  Insulin/IGF1 signalling mediates the effects of β2 -adrenergic agonist on muscle proteostasis and growth. J Cachexia Sarcopenia Muscle. 2019;10(2):455–475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6463755</ArticleId>
            <ArticleId IdType="pubmed">30932373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., et al.  Mechanism of activation of protein kinase B by insulin and IGF-1. The EMBO Journal. 1996;15(23):6541–6551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC452479</ArticleId>
            <ArticleId IdType="pubmed">8978681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butler A.A., Yakar S., Gewolb I.H., Karas M., Okubo Y., LeRoith D. Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology. 1998;121(1):19–26.</Citation>
        </Reference>
        <Reference>
          <Citation>LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews. 1995;16(2):143–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7540132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myers M.G., Grammer T.C., Wang L.M., Sun X.J., Pierce J.H., Blenis J., et al.  Insulin receptor substrate-1 mediates phosphatidylinositol 3’-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. Journal of Biological Chemistry. 1994;269(46):28783–28789.</Citation>
        </Reference>
        <Reference>
          <Citation>Bodine S.C., Stitt T.N., Gonzalez M., Kline W.O., Stover G.L., Bauerlein R., et al.  Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature Cell Biology. 2001;3(11):1014–1019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11715023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K., Zhu T., Guan K., Arbor A. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14651849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazaki M., Takemasa T. TSC2/Rheb signaling mediates ERK-dependent regulation of mTORC1 activity in C2C12 myoblasts. FEBS Open Bio. 2017;7(3):424–433.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang J.-Y., Zong C.S., Xia W., Yamaguchi H., Ding Q., Xie X., et al.  ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nature Cell Biology. 2008;10(2):138–148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2376808</ArticleId>
            <ArticleId IdType="pubmed">18204439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy S.K., Srivastava R.K., Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. Journal of Molecular Signaling. 2010;5(10)</Citation>
        </Reference>
        <Reference>
          <Citation>Mammucari C., Milan G., Romanello V., Masiero E., Rudolf R., Del Piccolo P., et al.  FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metabolism. 2007;6(6):458–471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18054315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117(3):399–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3619734</ArticleId>
            <ArticleId IdType="pubmed">15109499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonaldo P., Sandri M. Cellular and molecular mechanisms of muscle atrophy. Disease Models &amp; Mechanisms. 2013;6(1):25–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3529336</ArticleId>
            <ArticleId IdType="pubmed">23268536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milan G., Romanello V., Pescatore F., Armani A., Paik J.-H., Frasson L., et al.  Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nature Communications. 2015;6(6670)</Citation>
        </Reference>
        <Reference>
          <Citation>Fernandez-Marcos P.J., Auwerx J. Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. American Journal of Clinical Nutrition. 2011;93(4) 884S–890S.</Citation>
        </Reference>
        <Reference>
          <Citation>Singh S., Simpson R.L., Bennett R.G. Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α) Journal of Biological Chemistry. 2015;290(2):950–959.</Citation>
        </Reference>
        <Reference>
          <Citation>Handschin C., Kobayashi Y.M., Chin S., Seale P., Campbell K.P., Spiegelman B.M. PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes &amp; Development. 2007;21(7):770–783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1838529</ArticleId>
            <ArticleId IdType="pubmed">17403779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang X.-Y., Tse M.C.L., Hu X., Jia W.-H., Du G.-H., Chan C.B. Interaction of CREB and PGC-1α induces fibronectin type III domain-containing protein 5 expression in C2C12 myotubes. Cellular Physiology and Biochemistry. 2018;50(4):1574–1584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30359971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murgia M., Serrano A.L., Calabria E., Pallafacchina G., Lomo T., Schiaffino S. Ras is involved in nerve-activity-dependent regulation of muscle genes. Nature Cell Biology. 2000;2(3):142–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10707084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Pessin J.E. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Current Opinion in Clinical Nutrition and Metabolic Care. 2013;16(3):243–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4327989</ArticleId>
            <ArticleId IdType="pubmed">23493017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao X.-F., Zhou Y., Wang D.-Y., Lew K.-S., Richards A.M., Wang P. Urocortin-2 suppression of p38-MAPK signaling as an additional mechanism for ischemic cardioprotection. Molecular and Cellular Biochemistry. 2015;398(1–2):135–146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25245818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navegantes L.C., Resano N.M., Migliorini R.H., Kettelhut I.C. Effect of guanethidine-induced adrenergic blockade on the different proteolytic systems in rat skeletal muscle. American Journal of Physiology. 1999;277(5):E883–E889.</Citation>
        </Reference>
        <Reference>
          <Citation>Ryall J.G., Plant D.R., Gregorevic P., Sillence M.N., Lynch G.S. Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. The Journal of Physiology. 2004;555(Pt 1):175–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1664816</ArticleId>
            <ArticleId IdType="pubmed">14617677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan S., Head S.I. Age- and gender-related changes in contractile properties of non-atrophied EDL muscle. PLoS One. 2010;5(8)</Citation>
        </Reference>
        <Reference>
          <Citation>Waalkes T.P., Udenfriend S. A fluorometric method for the estimation of tyrosine in plasma and tissues. The Journal of Laboratory and Clinical Medicine. 1957;50(5):733–736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13476030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman C.A., Mabrey D.M., Frey J.W., Miu M.H., Schmidt E.K., Pierre P., et al.  Novel insights into the regulation of skeletal muscle protein synthesis as revealed by a new nonradioactive in vivo technique. Federation of American Societies for Experimental Biology Journal. 2011;25(3):1028–1039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3042844</ArticleId>
            <ArticleId IdType="pubmed">21148113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju J., Varadhachary A.S., Miller S.E., Weihl C.C. Quantitation of “autophagic flux” in mature skeletal muscle. Autophagy. 2010;6(7):929–935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3039739</ArticleId>
            <ArticleId IdType="pubmed">20657169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaughan J.M., Donaldson C.J., Fischer W.H., Perrin M.H., Rivier J.E., Sawchenko P.E., et al.  Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products. Endocrinology. 2013;154(4):1553–1564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3602626</ArticleId>
            <ArticleId IdType="pubmed">23493376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399(6736):601–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10376603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J.J., Zhang L., Bennett A.M. The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation. Molecular and Cellular Biology. 2005;25(11):4792–4803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1140620</ArticleId>
            <ArticleId IdType="pubmed">15899879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankiv S., Clausen T.H., Lamark T., Brech A., Bruun J.A., Outzen H., et al.  p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. Journal of Biological Chemistry. 2007;282(33):24131–24145.</Citation>
        </Reference>
        <Reference>
          <Citation>de Rooij J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., et al.  Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998;396(6710):474–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9853756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Reviews Molecular Cell Biology. 2011;12(1):21–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3390257</ArticleId>
            <ArticleId IdType="pubmed">21157483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyronnet S. Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochemical Pharmacology. 2000;60(8):1237–1243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11007962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng J., Klionsky D.J. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. “Protein modifications: beyond the usual suspects” review series. EMBO Reports. 2008;9(9):859–864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2529362</ArticleId>
            <ArticleId IdType="pubmed">18704115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjørkøy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., et al.  p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. The Journal of Cell Biology. 2005;171(4):603–614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2171557</ArticleId>
            <ArticleId IdType="pubmed">16286508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao J., Brault J.J., Schild A., Cao P., Sandri M., Schiaffino S., et al.  FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metabolism. 2007;6(6):472–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18054316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Proud C.G. Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circulation Research. 2002;91(9):821–829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12411397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelleher R.J., Govindarajan A., Jung H.-Y., Kang H., Tonegawa S. Translational control by MAPK signaling in long-term synaptic plasticity and memory. Cell. 2004;116(3):467–479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15016380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin J., Wu H., Tarr P.T., Zhang C.-Y., Wu Z., Boss O., et al.  Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002;418(6899):797–801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12181572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinkle R.T., Donnelly E., Cody D.B., Bauer M.B., Sheldon R.J., Isfort R.J. Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force. Journal of Muscle Research &amp; Cell Motility. 2004;25(7):539–547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15711884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reutenauer-patte J., Boittin F., Patthey-vuadens O., Ruegg U.T., Dorchies O.M. Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and epac-dependent pathways. AJPA. 2012;180(2):749–762.</Citation>
        </Reference>
        <Reference>
          <Citation>Hall J.E., Kaczor J.A.N.J., Hettinga B.P. Effects of a CRF2R agonist and exercise on mdx and wildtype skeletal muscle. Muscle &amp; Nerve. 2007;36(3):336–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17503504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jesinkey S.R., Korrapati M.C., Rasbach K.A., Beeson C.C., Schnellmann R.G. Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice. Journal of Pharmacology and Experimental Therapeutics. 2014;351(3):663–673.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang W., Yano N., Deng M., Mao Q., Shaw S.K., Tseng Y.-T. β-Adrenergic receptor-PI3K signaling crosstalk in mouse heart: elucidation of immediate downstream signaling cascades. PLoS One. 2011;6(10)</Citation>
        </Reference>
        <Reference>
          <Citation>Liu D., Bordicchia M., Zhang C., Fang H., Wei W., Li J.-L., et al.  Activation of mTORC1 is essential for β-adrenergic stimulation of adipose browning. Journal of Clinical Investigation. 2016;126(5):1704–1716.</Citation>
        </Reference>
        <Reference>
          <Citation>Przygodda F., Lautherbach N., Buzelle S.L., Goncalves D.A., Assis A.P., Paula-Gomes S., et al.  Sympathetic innervation suppresses the autophagic-lysosomal system in brown adipose tissue under basal and cold-stimulated conditions. Journal of Applied Physiology. 2020;128(4):855–871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32027543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baviera A.M., Zanon N.M., Navegantes L.C.C., Kettelhut I.C. Involvement of cAMP/Epac/PI3K-dependent pathway in the antiproteolytic effect of epinephrine on rat skeletal muscle. Molecular and Cellular Endocrinology. 2010;315(1–2):104–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19804812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navegantes L.C.C., Resano N.M.Z., Migliorini R.H., Kettelhut I.C. Catecholamines inhibit Ca(2+)-dependent proteolysis in rat skeletal muscle through beta(2)-adrenoceptors and cAMP. American Journal of Physiology. Endocrinology and Metabolism. 2001;281(3):E449–E454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11500299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navegantes L.C.C., Resano N.M.Z., Migliorini R.H. Role of adrenoceptors and cAMP on the catecholamine- induced inhibition of proteolysis in rat skeletal muscle. American Journal of Physiology. Endocrinology and Metabolism. 2000;279(3):E663–E668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10950836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ryall J.G., Sillence M.N., Lynch G.S. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. British Journal of Pharmacology. 2006;147(6):587–595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1751341</ArticleId>
            <ArticleId IdType="pubmed">16432501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonçalves D. a P., Silveira W.a., Lira E.C., Graça F.a., Paula-Gomes S., Zanon N.M., et al.  Clenbuterol suppresses proteasomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of Akt. American Journal of Physiology. Endocrinology and Metabolism. 2012;302(1):E123–E133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21952035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costelli P., García-Martínez C., Llovera M., Carbó N., López-Soriano F.J., Agell N., et al.  Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. Journal of Clinical Investigation. 1995;95(5):2367–2372.</Citation>
        </Reference>
        <Reference>
          <Citation>Lira E.C., Graca F.A., Goncalves D.A.P., Zanon N.M., Baviera A.M., Strindberg L., et al.  Cyclic adenosine monophosphate-phosphodiesterase inhibitors reduce skeletal muscle protein catabolism in septic rats. Shock. 2007;27(6):687–694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17505310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baviera A.M., Zanon N.M., Carvalho Navegantes L.C., Migliorini R.H., do Carmo Kettelhut I. Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats. American Journal of Physiology. Endocrinology and Metabolism. 2007;292(3):E702–E708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17077345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Handschin C., Rhee J., Lin J., Tarr P.T., Spiegelman B.M. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(12):7111–7116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC165838</ArticleId>
            <ArticleId IdType="pubmed">12764228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herzig S., Long F., Jhala U.S., Hedrick S., Quinn R., Bauer A., et al.  CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;413(6852):179–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11557984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandri M., Lin J., Handschin C., Yang W., Arany Z.P., Lecker S.H., et al.  PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(44):16260–16265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1637570</ArticleId>
            <ArticleId IdType="pubmed">17053067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng T., Li P., Yin X., Yan Z. PGC-1α promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac cachexia in mice. American Journal Of Pathology. 2011;178(4):1738–1748.</Citation>
        </Reference>
        <Reference>
          <Citation>Silveira W.A., Gonçalves D.A., Machado J., Lautherbach N., Lustrino D., Marcelo S.P., et al.  cAMP-dependent protein kinase inhibits FoxO activity and regulates skeletal muscle plasticity in mice. The FASEB Journal. 2020;34(9):12946–12962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32772437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borg M.L., Massart J., Schönke M., Barbosa T.D.C., Guo L., Wade M., et al.  Modified UCN2 peptide acts as an insulin sensitizer in skeletal muscle of obese mice. Diabetes. 2019;68(7):1403–1414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31010957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chao H., Li H., Grande R., Lira V., Yan Z., Harris T.E., et al.  Involvement of mTOR in type 2 CRF receptor inhibition of insulin signaling in muscle cells. Molecular Endocrinology. 2015;29(6):831–841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4447643</ArticleId>
            <ArticleId IdType="pubmed">25875045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mei F.C., Qiao J., Tsygankova O.M., Meinkoth J.L., Quilliam L.A., Cheng X. Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. Journal of Biological Chemistry. 2002;277(13):11497–11504.</Citation>
        </Reference>
        <Reference>
          <Citation>Brennesvik E.O., Ktori C., Ruzzin J., Jebens E., Shepherd P.R., Jensen J. Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline. Cellular Signalling. 2005;17(12):1551–1559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15908181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keiper M., Stope M.B., Szatkowski D., Böhm A., Tysack K., Vom Dorp F., et al.  Epac- and Ca2+ -controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. Journal of Biological Chemistry. 2004;279(45):46497–46508.</Citation>
        </Reference>
        <Reference>
          <Citation>Jones N.C., Fedorov Y.V., Rosenthal R.S. ERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusion. Journal of Cellular Physiology. 2001;186(1):104–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11147804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokoyama T., Takano K., Yoshida A., Katada F., Sun P., Takenawa T., et al.  DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation. The Journal of Cell Biology. 2007;177(5):781–793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2064279</ArticleId>
            <ArticleId IdType="pubmed">17535970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bueno O.F., De Windt L.J., Tymitz K.M., Witt S.a., Kimball T.R., Klevitsky R., et al.  The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. The EMBO Journal. 2000;19(23):6341–6350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC305855</ArticleId>
            <ArticleId IdType="pubmed">11101507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueyama T., Kawashima S., Sakoda T., Rikitake Y., Ishida T., Kawai M., et al.  Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. Journal of Molecular and Cellular Cardiology. 2000;32(6):947–960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10888249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H., Scheffler J.M., Zeng C., Pleitner J.M., Hannon K.M., Grant A.L., et al.  Mitogen-activated protein kinase signaling is necessary for the maintenance of skeletal muscle mass. American Journal of Physiology - Cell Physiology. 2009;296(5):C1040–C1048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19295173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi H., Zeng C., Ricome A., Hannon K.M., Grant A.L., Gerrard D.E. Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles. American Journal of Physiology - Cell Physiology. 2007;292(5):C1681–C1689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17151143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinkle R.T., Lefever F.R., Dolan E.T., Reichart D.L., Dietrich J.A., Gropp K.E., et al.  Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice. BMC Medicine. 2007;5(18)</Citation>
        </Reference>
        <Reference>
          <Citation>Chanalaris A., Lawrence K.M., Stephanou A., Knight R.D., Hsu S.Y., Hsueh A.J.W., et al.  Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. Journal of Molecular and Cellular Cardiology. 2003;35(10):1295–1305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14519439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(37):13489–13494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC518784</ArticleId>
            <ArticleId IdType="pubmed">15342917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brar B.K., Jonassen A.K., Egorina E.M., Chen A., Negro A., Perrin M.H., et al.  Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 2004;145(1):24–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12970163</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
